Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. reports developments in its global, full-service clinical contract research organization business, providing Phase I-IV clinical development services to biotechnology, pharmaceutical and medical device companies. Company news centers on quarterly and annual operating results, conference-call announcements and performance measures used in the CRO model, including revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios.
Updates also describe Medpace's therapeutic and regulatory expertise across major development areas such as oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective programs.
Medpace Holdings, Inc. (Nasdaq: MEDP) will report its Q4 and fiscal 2020 financial results on February 15, 2021. A conference call will follow on February 16, 2021, at 9:00 a.m. ET, accessible via phone or webcast. Medpace, based in Cincinnati, offers Phase I-IV clinical development services to biotech and pharmaceutical industries, employing around 3,400 staff across 39 countries as of September 30, 2020. The company's focus includes oncology, cardiology, and more, aiming to accelerate the development of safe medical therapeutics.
Medpace Holdings, Inc. (Nasdaq: MEDP) announced a 6.5% increase in third quarter 2020 revenue to $230.4 million compared to $216.2 million in 2019. The net book-to-bill ratio stood at 1.37x with net new business awards of $315.4 million. GAAP net income reached $41.5 million ($1.09 per diluted share), representing an 18.0% net income margin. EBITDA surged by 49.4% to $51.9 million. The company forecasts 2020 revenue between $880 million and $920 million and expects 2021 revenue to range from $1.050 billion to $1.125 billion.